Skip to main
ALLO

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics Inc has demonstrated a strategic pivot by adopting standard FC lymphodepletion in its ALPHA3 trial, aimed at enhancing patient safety while simplifying the treatment protocol, which may lead to improved protocol adherence and real-world adoption. The company also reported high patient consent rates for minimal residual disease (MRD) screening, indicating strong engagement in the study, which bodes well for recruitment and the potential scalability of their T-cell therapies. Additionally, positive feedback from investigators regarding the regimen's simplification suggests that the approach may reduce complexity and infection risks, further supporting Allogene's vision of broader patient eligibility and potential market reach.

Bears say

Allogene Therapeutics Inc faces significant risks related to the approval of its clinical assets, as delays or failures in achieving regulatory approval could adversely affect the company's stock value. Additionally, the inherent uncertainties in clinical trials introduce the possibility that the company's products may not demonstrate sufficient efficacy or safety, which could further jeopardize their potential commercialization. Given these factors, combined with regulatory and commercial risks, the outlook for Allogene’s financial performance remains unfavorable.

ALLO has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 10 analysts, ALLO has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.